Ponatinib

• Safety and efficacy of treatment combination with ponatinib and asciminib in chronic myeloid leukemia patients resistant to ponatinib and/or… Pending
  2025-521126-15-00 Phase II 1 country Grupo Espanol De Leucemia Mieloide Cronica (GELMC)
• A Global Study Testing the New Drug Olverembatinib combined with chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Pos… Recruiting
  2024-511496-14-00 Phase III 7 countries Ascentage Pharma Group Inc.
• GRAALL 2024 - A 3-cohort Randomized Study evaluating the role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Tran… Recruiting
  2024-511437-35-00 Phase II/III 2 countries Assistance Publique Hopitaux De Paris
• EWALL-PH-03: An open label, 2-arm, Randomised phase II study to Compare the Safety and Efficacy of Ponatinib plus Chemotherapy with Imatinib… Recruiting
  2023-505330-95-01 Phase II 3 countries Cardiff University
• FINPROVE - The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs Recruiting
  2024-517478-68-01 Phase II 1 country HUS-Yhtymae
• A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting
  2024-517966-40-00 Phase II 1 country Goethe University Frankfurt
• The study's aim is to treat adult patients affected by Ph-like ALL, a Philadelphianegative ALL subtype, with a combination of the tyrosine k… Recruiting
  2023-510240-20-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
• A study evaluating the safety and efficacy of ponatinib for the treatment of recurrent or refractory leukemias or solid tumors in children Recruiting
  2023-509699-41-00 Phase I/II 6 countries Incyte Biosciences International S.a.r.l.
• Trial aimed at examinate the functionality and effectiveness of the drug "IO" in adult patients with a rare form of cancer that affect the c… Recruiting
  2023-510516-39-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
• A Patient guided dose reduction strategy of tyrosine kinase inhibitors in chronic myeloid leukaemia: RODEO study Ended
  2024-516511-24-00 Phase III/IV 1 country Stichting Radboud universitair medisch centrum
• The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and… Ended
  2023-508968-30-00 Phase III 1 country Fondazione Gimema Franco Mandelli Onlus
• The aim of the study is to evaluate the efficacy of Ponatinib, either alone or in combination with chemotherapy, in inducing remission in pa… Ended
  2024-516868-28-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
• OPEN LABEL PHASE 2 STUDY ON THE EFFICACY AND TOLERANCE OF A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN A… Ended
  2024-516048-24-00 Phase II 1 country Centre Hospitalier De Versailles
• An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Participants with… Ended
  2023-508463-71-00 Phase III 6 countries Takeda Development Center Americas Inc.
• With Ponatinib on the track for treatment-free-remission in chronic myeloid leukemia Ended
  2024-518971-76-00 Phase II 1 country Heidelberg University
• Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Reinduction and second stop of TKI with Ponatinib in CML in … Ended
  2023-508993-27-00 Phase II 1 country Fundacion Cris De Investigacion Para Vencer El Cancer
• A study of Iclusig (ponatinib), an oral kinase-inhibitor treatment administered, by standard dose or reduced doses, for patients with Philad… Ended
  2024-514516-27-00 Phase II 2 countries Takeda Development Center Americas Inc.

Showing 1–17 of 17 trials